Literature DB >> 19699071

Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study.

F Affuso1, A Ruvolo, F Micillo, L Saccà, S Fazio.   

Abstract

BACKGROUND AND AIMS: Some nutraceuticals are prescribed as lipid-lowering substances. However, doubts remain about their efficacy. We evaluated the effects of a nutraceutical combination (NC), consisting of 500 mg berberine, 200mg red yeast rice and 10mg policosanols, on cholesterol levels and endothelial function in patients with hypercholesterolemia. METHODS AND
RESULTS: In this single centre, randomized, double-blind, placebo-controlled study, 50 hypercholesterolemic patients (26 males and 24 females, mean age 55±7 years, total cholesterol 6.55±0.75 mmol/l, BMI 28±3.5) were randomized to 6 weeks of treatment with a daily oral dose of NC (25 patients) or placebo (25 patients). In a subsequent open-label extension of 4 weeks, the whole sample received NC. The main outcome measure was decrease total cholesterol (C) levels in the NC arm. Secondary outcome measures were decreased low-density lipoprotein cholesterol (LDL-C) and triglyceride levels, and improved endothelial-dependent flow-mediated dilation (FMD) and insulin sensitivity in relation to NC. Evaluation of absolute changes from baseline showed significant reductions in NC versus placebo for C and LDL-C (C: -1.14±0.88 and -0.03±0.78 mmol/l, p<0.001; LDL-C: -1.06±0.75 and -00.4±0.54 mmol/l, p<0.001), and a significant improvement of FMD (3±4% and 0±3% respectively, p<0.05). After the extension phase, triglyceride levels decreased significantly from 1.57±0.77 to 1.26±0.63 mmol/l, p<0.05 and insulin sensitivity improved in a patient subgroup with insulin resistance at baseline (HOMA: from 3.3±0.4 to 2.5±1.3, p<0.05). No adverse effect was reported.
CONCLUSIONS: This NC reduces cholesterol levels. The reduction is associated with improved endothelial function and insulin sensitivity.
Copyright © 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19699071     DOI: 10.1016/j.numecd.2009.05.017

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  35 in total

Review 1.  Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience.

Authors:  Natalie C Ward; Jing Pang; Jacqueline D M Ryan; Gerald F Watts
Journal:  Clin Cardiol       Date:  2018-01-24       Impact factor: 2.882

2.  Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel.

Authors:  Arrigo F G Cicero; Alessandro Colletti; Gani Bajraktari; Olivier Descamps; Dragan M Djuric; Marat Ezhov; Zlatko Fras; Niki Katsiki; Michel Langlois; Gustavs Latkovskis; Demosthenes B Panagiotakos; Gyorgy Paragh; Dimitri P Mikhailidis; Olena Mitchenko; Bernhard Paulweber; Daniel Pella; Christos Pitsavos; Željko Reiner; Kausik K Ray; Manfredi Rizzo; Amirhossein Sahebkar; Maria-Corina Serban; Laurence S Sperling; Peter P Toth; Dragos Vinereanu; Michal Vrablík; Nathan D Wong; Maciej Banach
Journal:  Arch Med Sci       Date:  2017-08-04       Impact factor: 3.318

Review 3.  Cholesterol-Lowering Nutraceuticals Affecting Vascular Function and Cardiovascular Disease Risk.

Authors:  Vanessa Bianconi; Massimo Raffaele Mannarino; Amirhossein Sahebkar; Teresa Cosentino; Matteo Pirro
Journal:  Curr Cardiol Rep       Date:  2018-05-25       Impact factor: 2.931

4.  Cardiovascular and metabolic effects of Berberine.

Authors:  Flora Affuso; Valentina Mercurio; Valeria Fazio; Serafino Fazio
Journal:  World J Cardiol       Date:  2010-04-26

5.  A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome.

Authors:  Flora Affuso; Valentina Mercurio; Antonio Ruvolo; Concetta Pirozzi; Filomena Micillo; Guido Carlomagno; Fabrizia Grieco; Serafino Fazio
Journal:  World J Cardiol       Date:  2012-03-26

6.  Development of ITS sequence-based markers to distinguish Berberis aristata DC. from B. lycium Royle and B. asiatica Roxb.

Authors:  Subramani Paranthaman Balasubramani; Gurinder Singh Goraya; Padma Venkatasubramanian
Journal:  3 Biotech       Date:  2011-01-18       Impact factor: 2.406

7.  Berberine and monacolin effects on the cardiovascular risk profile of women with oestroprogestin-induced hypercholesterolemia.

Authors:  Arrigo F G Cicero; Alessandra Reggi; Angelo Parini; Martino Morbini; Martina Rosticci; Elisa Grandi; Claudio Borghi
Journal:  High Blood Press Cardiovasc Prev       Date:  2014-04-12

8.  The Effects of a New Generation of Nutraceutical Compounds on Lipid Profile and Glycaemia in Subjects with Pre-hypertension.

Authors:  Alberto Mazza; Laura Schiavon; Gianluca Rigatelli; Gioia Torin; Salvatore Lenti
Journal:  High Blood Press Cardiovasc Prev       Date:  2019-07-27

Review 9.  Nutraceutical therapies for atherosclerosis.

Authors:  Joe W E Moss; Dipak P Ramji
Journal:  Nat Rev Cardiol       Date:  2016-07-07       Impact factor: 32.419

10.  Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control.

Authors:  Francesco Di Pierro; Nicola Villanova; Federica Agostini; Rebecca Marzocchi; Valentina Soverini; Giulio Marchesini
Journal:  Diabetes Metab Syndr Obes       Date:  2012-07-17       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.